MedTrace Logo

Experimental Medication For the Treatment of Generalized Anxiety Disorder

NCT00097708 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 511

Last updated 2014-10-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether an experimental anti-anxiety medication is effective in the treatment of Generalized Anxiety Disorder.

Conditions

  • Anxiety Disorder

Interventions

DRUG

experimental anti-anxiety drug

Sponsors & Collaborators

Principal Investigators

  • Murray Stein, MD · University of California, San Diego

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Completion
2005-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00097708 on ClinicalTrials.gov